Woodline Partners’s Silence Therapeutics SLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.28M Buy
+300,000
New +$3.65M 0.01% 811
2025
Q4
– Sell
-62,459
Closed -$324K – 1107
2025
Q3
$324K Hold
62,459
– – ﹤0.01% 855
2025
Q2
$362K Sell
62,459
-72,033
-54% -$309K ﹤0.01% 878
2025
Q1
$379K Sell
134,492
-364,240
-73% -$1.78M ﹤0.01% 842
2024
Q4
$3.43M Buy
498,732
+91,829
+23% +$1.18M 0.02% 561
2024
Q3
$7.4M Buy
406,903
+316,041
+348% +$5.88M 0.06% 339
2024
Q2
$1.73M Sell
90,862
-147,518
-62% -$3.14M 0.02% 433
2024
Q1
$5.15M Buy
238,380
+189,108
+384% +$4.11M 0.05% 356
2023
Q4
$856K Sell
49,272
-117,380
-70% -$1.32M 0.01% 412
2023
Q3
$1.64M Sell
166,652
-72,708
-30% -$537K 0.02% 415
2023
Q2
$1.32M Buy
239,360
+95,676
+67% +$577K 0.02% 466
2023
Q1
$891K Buy
143,684
+20,643
+17% +$243K 0.01% 482
2022
Q4
$1.88M Buy
123,041
+7,921
+7% +$104K 0.03% 489
2022
Q3
$1.16M Buy
+115,120
New +$1.21M 0.02% 525

Other funds holding SLN

Woodline Partners's SLN Position: Q3 2026 in Review

Woodline Partners opened a new position in Silence Therapeutics (SLN) in Q3 2026: 300,000 shares worth $3.28M. The stake represents 0.01% of the portfolio and ranks #811 among its holdings. This is a return to the name: Woodline Partners previously reported a position in SLN as recently as Q3 2025.

Woodline Partners first reported a position in SLN in Q3 2022 and has held it in 14 quarters since. The position peaked at $7.4M in Q3 2024. 92 funds tracked by Wall St. Rank hold SLN as of Q3 2026.

  • Woodline Partners held 300,000 shares of Silence Therapeutics worth $3.28M as of Q3 2026.
  • Silence Therapeutics was a new Woodline Partners position in Q3 2026.
  • Silence Therapeutics made up 0.01% of Woodline Partners's portfolio in Q3 2026, its #811 holding.
  • Woodline Partners first reported a position in Silence Therapeutics in Q3 2022 and has held it in 14 quarters since.
  • Woodline Partners's Silence Therapeutics position peaked at $7.4M in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.